CAIHealthcare · BiotechnologyThe 14 Wall Street analysts covering Caris Life Sciences, Inc. hold a median 12-month price target of $35 — +5.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Caris Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (71): The business earns solid, repeatable profits on what it owns.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CAI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.4% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | BTIG | Maintains | Buy | $33 → $38 |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Hold | — |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Hold | $22 → $30 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | $25 → $35 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $30 → $36 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | — |
| 9 Sept 2026 | UBS | Initiates | Neutral | $28 |
| 9 Sept 2026 | UBS | Initiates | Neutral | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | $32 → $33 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $25 → $26 |
| 5 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $30 → $25 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 2 July 2026 | BTIG | Reiterates | Buy | — |
| 2 July 2026 | BTIG | Reiterates | Buy | $32 |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 8 May 2026 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CAI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Caris Life Sciences, Inc. returned +6.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 38% of US stocks
Cheaper than 14% of US stocks
Cheaper than 6% of US stocks
Cheaper than 4% of US stocks
Higher than 84% of US stocks
Higher than 73% of US stocks
Higher than 81% of US stocks
Higher than 65% of US stocks
Higher than 70% of US stocks
Higher than 81% of US stocks
Higher than 90% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Caris Life Sciences, Inc. has a market value of $9.4B and an enterprise value of $8.9B.
Revenue in the twelve months to 30 June 2026: $989.6M. The latest quarter grew 45.4% year on year.
Net income over the same four quarters: $105.1M, a 10.6% net margin.
Diluted earnings per share, trailing twelve months: $0.36.
Free cash flow in the twelve months to 30 June 2026: $124.0M.
Caris Life Sciences, Inc. spent $21.5M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 19.7×; forward P/E: 89.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Caris Life Sciences, Inc. employs 1,846 people — $536K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Caris Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Caris Life Sciences, Inc.’s Q3 2026 earnings call. The provided excerpt contains no details from the call.
Why it matters — The transcript is a source for CAI watchers, but the excerpt provides no information about the company’s performance or outlook.
Caris Life Sciences raised its full-year revenue outlook after third-quarter sales rose 27%, supported by accelerating cancer-testing volume growth. Quarterly profit declined as the company increased spending on its sales force, marketing and new tests.
Why it matters — The update highlights stronger revenue and testing-volume growth alongside lower quarterly profit from increased investment spending.
Caris Life Sciences reported Q3 earnings of $0.05 per share, above the Zacks Consensus Estimate of $0.03. Earnings were $0.08 per share in the year-ago quarter.
Why it matters — CAI watchers may note that quarterly earnings exceeded the consensus estimate, while remaining below the year-ago result.
Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year, citing strong molecular profiling services performance. The company raised its 2026 revenue guidance to $1.04 billion–$1.05 billion, representing expected growth of 28%–29%.
Why it matters — The results and higher revenue guidance provide CAI watchers with an update on the company’s reported growth and outlook.
Zacks says Caris Life Sciences does not have the two key ingredients associated with a likely earnings beat ahead of its upcoming report. The item points readers to expectations for the report.
Why it matters — CAI watchers may note the article’s caution about the likelihood of an earnings beat as they follow the upcoming report.
The 14 Wall Street analysts covering Caris Life Sciences, Inc. have a median 12-month price target of $35, with estimates ranging from $22 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Caris Life Sciences, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caris Life Sciences, Inc. 37 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Caris Life Sciences, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (71 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +5.4% from the last close, and Ticker Nerd's factor model ranks Caris Life Sciences, Inc. 37 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Caris Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $38 over the next 12 months.
Caris Life Sciences, Inc. returned +6.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Caris Life Sciences, Inc. is a precision medicine and diagnostic technology company focused on applying comprehensive molecular information and artificial intelligence to healthcare.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Caris Life Sciences, Inc.’s Q3 2026 earnings call. The provided excerpt contains no details from the call.
Caris Life Sciences, Inc. is a precision medicine and diagnostic technology company focused on applying comprehensive molecular information and artificial intelligence to healthcare. Its current services include molecular profiling, genomic and diagnostic testing, and anatomic pathology solutions that help characterize disease at the patient level. The company’s platforms support biomarker discovery, treatment selection, disease monitoring, clinical research, and the identification of potential therapeutic targets. Caris Life Sciences, Inc. primarily serves oncology, where detailed tumor analysis can inform personalized care, while also supporting academic institutions, healthcare providers, and biopharmaceutical companies. Its capabilities combine laboratory diagnostics, bioinformatics, data analysis, and machine-learning tools to organize complex biological information for clinical and research applications. By connecting diagnostic services with drug development and precision medicine workflows, Caris Life Sciences, Inc. occupies a specialized role at the intersection of life sciences, artificial intelligence, laboratory medicine, and biopharmaceutical innovation. The company’s offerings contribute to the use of molecular data in modern disease management and therapeutic development.
CEO Dr. David Dean Halbert M.D. · 1,846 employees · United States · https://www.carislifesciences.com
